RARE PE Ratio & Valuation, Is RARE Overvalued

Historical Valuation

Ultragenyx Pharmaceutical Inc (RARE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.07 is considered Undervalued compared with the five-year average of -8.41. The fair price of Ultragenyx Pharmaceutical Inc (RARE) is between 41.37 to 88.53 according to relative valuation method. Compared to the current price of 19.38 USD , Ultragenyx Pharmaceutical Inc By Undervalued By 53.15%.

Relative Value

Fair Zone

41.37-88.53

Current Price：19.38

53.15%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Ultragenyx Pharmaceutical Inc (RARE) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Ultragenyx Pharmaceutical Inc (RARE) has a current Price-to-Book (P/B) ratio of 248.06. Compared to its 3-year average P/B ratio of 55.10, the current P/B ratio is approximately 350.20% higher. Relative to its 5-year average P/B ratio of 34.28, the current P/B ratio is about 623.64% higher. Ultragenyx Pharmaceutical Inc (RARE) has a Forward Free Cash Flow (FCF) yield of approximately -19.86%. Compared to its 3-year average FCF yield of -14.09%, the current FCF yield is approximately 40.92% lower. Relative to its 5-year average FCF yield of -12.36%, the current FCF yield is about 60.73% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RARE competitors is 13.55, providing a benchmark for relative valuation. Ultragenyx Pharmaceutical Inc Corp (RARE.O) exhibits a P/S ratio of 3.07, which is -77.35% above the industry average. Given its robust revenue growth of 25.72%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RARE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RARE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RARE currently overvalued or undervalued?

Ultragenyx Pharmaceutical Inc (RARE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.07 is considered Undervalued compared with the five-year average of -8.41. The fair price of Ultragenyx Pharmaceutical Inc (RARE) is between 41.37 to 88.53 according to relative valuation method. Compared to the current price of 19.38 USD, Ultragenyx Pharmaceutical Inc is Undervalued By 53.15%.

What is Ultragenyx Pharmaceutical Inc (RARE) fair value?

RARE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Ultragenyx Pharmaceutical Inc (RARE) is between 41.37 to 88.53 according to relative valuation method.

How does RARE's valuation metrics compare to the industry average?

The average P/S ratio for RARE's competitors is 13.55, providing a benchmark for relative valuation. Ultragenyx Pharmaceutical Inc Corp (RARE) exhibits a P/S ratio of 3.07, which is -77.35% above the industry average. Given its robust revenue growth of 25.72%, this premium appears sustainable.

What is the current P/B ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Mar 30 2026?

As of Mar 30 2026, Ultragenyx Pharmaceutical Inc (RARE) has a P/B ratio of 248.06. This indicates that the market values RARE at 248.06 times its book value.

What is the current FCF Yield for Ultragenyx Pharmaceutical Inc (RARE) as of Mar 30 2026?

As of Mar 30 2026, Ultragenyx Pharmaceutical Inc (RARE) has a FCF Yield of -19.86%. This means that for every dollar of Ultragenyx Pharmaceutical Inc's market capitalization, the company generates -19.86 cents in free cash flow.

What is the current Forward P/E ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Mar 30 2026?

As of Mar 30 2026, Ultragenyx Pharmaceutical Inc (RARE) has a Forward P/E ratio of -4.95. This means the market is willing to pay $-4.95 for every dollar of Ultragenyx Pharmaceutical Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Mar 30 2026?

As of Mar 30 2026, Ultragenyx Pharmaceutical Inc (RARE) has a Forward P/S ratio of 3.07. This means the market is valuing RARE at $3.07 for every dollar of expected revenue over the next 12 months.

RARE Valuation